Get the Stockscreener App
1.26
10.04%
0.115
Pre-market:
1.26
Citius Pharmaceuticals Inc stock is traded at $1.26, with a volume of 417.41K.
It is up +10.04% in the last 24 hours and down -7.35% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$1.145
Open:
$1.15
24h Volume:
417.41K
Relative Volume:
0.54
Market Cap:
$23.27M
Revenue:
-
Net Income/Loss:
$-39.14M
P/E Ratio:
-0.2111
EPS:
-5.97
Net Cash Flow:
$-28.20M
1W Performance:
-10.00%
1M Performance:
-7.35%
6M Performance:
+44.16%
1Y Performance:
-65.38%
1-Day Range:
$1.1181
$1.265
1-Week Range:
$1.1181
$1.48
52-Week Range:
$0.65
$5.95
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.26 | 21.15M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
How Citius Pharmaceuticals Inc. (47N0) stock reacts to fiscal policiesJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
Is Citius Pharmaceuticals Inc. (47N0) stock good for wealth creation2025 Major Catalysts & Weekly Sector Rotation Insights - Newser
CTXR: Analyst Jason Kolbert Maintains 'Buy' Rating with $6 Price Target | CTXR Stock News - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - PR Newswire
How supply shortages influence Citius Pharmaceuticals Inc. (47N0) stockWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
How Citius Pharmaceuticals Inc. (47N0) stock responds to bond market2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand - Barchart.com
Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ
How Citius Pharmaceuticals Inc. (47N0) stock reacts to new regulations2025 Analyst Calls & Momentum Based Trading Signals - Newser
Is Citius Pharmaceuticals Inc. (47N0) stock vulnerable to rate hikesDollar Strength & Capital Efficiency Focused Ideas - Newser
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Why Citius Pharmaceuticals Inc. (47N0) stock is a must watch tickerWeekly Loss Report & Reliable Entry Point Trade Alerts - Newser
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN
Will Citius Pharmaceuticals Inc. (47N0) stock boost dividends furtherProduct Launch & Stepwise Trade Signal Implementation - Newser
How Citius Pharmaceuticals Inc. (47N0) stock moves in volatile trading sessions - Newser
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Citius Pharmaceuticals, Inc. Launches LYMPHIR for CTCL Treatment - TradingView
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - PR Newswire
Why Citius Pharmaceuticals Inc. stock remains resilientIPO Watch & AI Forecasted Entry/Exit Points - BỘ NỘI VỤ
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch - Aktiellt
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting - 富途牛牛
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading - Nasdaq
Citius Oncology to advance LYMPHIR launch with AI technology By Investing.com - Investing.com Nigeria
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration - Placera.se
Citius Oncology stock soars on expanded AI collaboration for LYMPHIR launch - Investing.com
Citius Oncology to advance LYMPHIR launch with AI technology - Investing.com India
Citius Oncology (Nasdaq: CTOR) taps Verix AI to support Q4 2025 LYMPHIR CTCL launch - Stock Titan
Can Citius Pharmaceuticals Inc. (47N0) stock sustain free cash flow - newser.com
How Citius Pharmaceuticals Inc. stock reacts to Fed rate cutsStop Loss & Weekly High Potential Stock Alerts - newser.com
Can Citius Pharmaceuticals Inc. (47N0) stock withstand sector downturns2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock good for long term investingMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
Visual analytics tools that track Citius Pharmaceuticals Inc. performanceJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Will Citius Pharmaceuticals Inc. stock deliver better than expected guidance2025 Key Highlights & Consistent Return Investment Signals - newser.com
Is Citius Pharmaceuticals Inc. stock attractive for growth ETFsDollar Strength & Free Reliable Trade Execution Plans - newser.com
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):